Vector  ||| S:0 E:7 ||| JJ
vaccination  ||| S:7 E:19 ||| NN
and  ||| S:19 E:23 ||| CC
vector  ||| S:23 E:30 ||| JJ
targeted  ||| S:30 E:39 ||| JJ
chemotherapy  ||| S:39 E:52 ||| NN
in  ||| S:52 E:55 ||| IN
solid  ||| S:55 E:61 ||| JJ
tumors  ||| S:61 E:68 ||| JJ
Gene  ||| S:68 E:73 ||| NNP
therapy  ||| S:73 E:81 ||| NN
is  ||| S:81 E:84 ||| VBZ
one  ||| S:84 E:88 ||| CD
of  ||| S:88 E:91 ||| IN
the  ||| S:91 E:95 ||| DT
promising  ||| S:95 E:105 ||| JJ
treatment  ||| S:105 E:115 ||| NN
modalities  ||| S:115 E:126 ||| NN
in  ||| S:126 E:129 ||| IN
cancer  ||| S:129 E:136 ||| NN
therapy ||| S:136 E:143 ||| NN
.  ||| S:143 E:145 ||| .
The  ||| S:145 E:149 ||| DT
current  ||| S:149 E:157 ||| JJ
gene  ||| S:157 E:162 ||| NN
therapy  ||| S:162 E:170 ||| NN
modalities  ||| S:170 E:181 ||| NNS
are  ||| S:181 E:185 ||| VBP
mainly  ||| S:185 E:192 ||| RB
focused  ||| S:192 E:200 ||| VBN
on  ||| S:200 E:203 ||| IN
the  ||| S:203 E:207 ||| DT
introduction  ||| S:207 E:220 ||| NN
of  ||| S:220 E:223 ||| IN
suppressed  ||| S:223 E:234 ||| JJ
tumor  ||| S:234 E:240 ||| NN
suppressor  ||| S:240 E:251 ||| NN
genes  ||| S:251 E:257 ||| NNS
into  ||| S:257 E:262 ||| IN
cancer  ||| S:262 E:269 ||| NN
cells ||| S:269 E:274 ||| NNS
,  ||| S:274 E:276 ||| ,
modulation  ||| S:276 E:287 ||| VBG
of  ||| S:287 E:290 ||| IN
anti-tumoral  ||| S:290 E:303 ||| JJ
immune  ||| S:303 E:310 ||| JJ
response ||| S:310 E:318 ||| NN
,  ||| S:318 E:320 ||| ,
and  ||| S:320 E:324 ||| CC
the  ||| S:324 E:328 ||| DT
suicide  ||| S:328 E:336 ||| NN
gene  ||| S:336 E:341 ||| NN
therapy  ||| S:341 E:349 ||| NN
by  ||| S:349 E:352 ||| IN
introducing  ||| S:352 E:364 ||| VBG
pro-drug-activating  ||| S:364 E:384 ||| JJ
enzyme  ||| S:384 E:391 ||| JJ
genes  ||| S:391 E:397 ||| NNS
into  ||| S:397 E:402 ||| IN
the  ||| S:402 E:406 ||| DT
tumor  ||| S:406 E:412 ||| NN
cells ||| S:412 E:417 ||| NNS
.  ||| S:417 E:419 ||| .
Currently ||| S:419 E:428 ||| RB
,  ||| S:428 E:430 ||| ,
various  ||| S:430 E:438 ||| JJ
gene  ||| S:438 E:443 ||| NN
therapy  ||| S:443 E:451 ||| NN
trials  ||| S:451 E:458 ||| NNS
are  ||| S:458 E:462 ||| VBP
being  ||| S:462 E:468 ||| VBG
conducted  ||| S:468 E:478 ||| VBN
in  ||| S:478 E:481 ||| IN
cancer  ||| S:481 E:488 ||| NN
patients ||| S:488 E:496 ||| NNS
.  ||| S:496 E:498 ||| .
However ||| S:498 E:505 ||| RB
,  ||| S:505 E:507 ||| ,
the  ||| S:507 E:511 ||| DT
early  ||| S:511 E:517 ||| JJ
results  ||| S:517 E:525 ||| NNS
of  ||| S:525 E:528 ||| IN
these  ||| S:528 E:534 ||| DT
trials  ||| S:534 E:541 ||| NNS
conducted  ||| S:541 E:551 ||| VBN
so  ||| S:551 E:554 ||| RB
far  ||| S:554 E:558 ||| RB
are  ||| S:558 E:562 ||| VBP
not  ||| S:562 E:566 ||| RB
so  ||| S:566 E:569 ||| RB
encouraging ||| S:569 E:580 ||| VBG
.  ||| S:580 E:582 ||| .
Combination  ||| S:582 E:594 ||| NN
of  ||| S:594 E:597 ||| IN
gene  ||| S:597 E:602 ||| NN
therapy  ||| S:602 E:610 ||| NN
strategies  ||| S:610 E:621 ||| NNS
with  ||| S:621 E:626 ||| IN
conventional  ||| S:626 E:639 ||| JJ
treatment  ||| S:639 E:649 ||| NN
modalities  ||| S:649 E:660 ||| VBZ
such  ||| S:660 E:665 ||| JJ
as  ||| S:665 E:668 ||| IN
chemotherapy ||| S:668 E:680 ||| NN
,  ||| S:680 E:682 ||| ,
immunotherapy  ||| S:682 E:696 ||| NN
or  ||| S:696 E:699 ||| CC
radiotherapy  ||| S:699 E:712 ||| NN
has  ||| S:712 E:716 ||| VBZ
yielded  ||| S:716 E:724 ||| VBN
encouraging  ||| S:724 E:736 ||| JJ
results  ||| S:736 E:744 ||| NNS
in  ||| S:744 E:747 ||| IN
experimental  ||| S:747 E:760 ||| JJ
models  ||| S:760 E:767 ||| NNS
and  ||| S:767 E:771 ||| CC
early  ||| S:771 E:777 ||| JJ
clinical  ||| S:777 E:786 ||| JJ
trials ||| S:786 E:792 ||| NNS
.  ||| S:792 E:794 ||| .
